Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 13/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760176 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13701373 | 0.74 | CTSS (0.41) | ALDH1A1CTSSMAPTSMN1; SMN2 | |
| SCHEMBL2760089 | 0.72 | HTT (0.50) | ALDH1A1CTSSNPC1RAB9AMAPT | |
| SCHEMBL14996224 | 0.72 | CTSS (0.40) | ALDH1A1CTSSMAPTSMN1; SMN2 | |
| SCHEMBL2736388 | 0.71 | CTSS (0.36) | ALDH1A1CTSSMAPTSMN1; SMN2 | |
| SCHEMBL12619275 | 0.69 | CTSS (0.38) | CTSSMAPTSMN1; SMN2 | |
| SCHEMBL13617149 | 0.67 | HTT (0.34) | CTSSMAPTSMN1; SMN2 | |
| SCHEMBL19229610 | 0.65 | HTT (0.54) | ALDH1A1NPC1MAPTSMN1; SMN2HRH3 | |
| SCHEMBL11989259 | 0.65 | CTSS (0.34) | CTSS | |
| SCHEMBL12652971 | 0.65 | POLB (0.40) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7488823-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | ALDH1A1 4357/4885CTSS 3074/4885NPC1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.